medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2004, Number S1

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2004; 17 (S1)

Medical treatment of pulmonary hypertension: conventional therapies

Hernández RJP, Narváez DR, Dorantes GJ, Oseguera MJ

Language: Spanish
References: 14
Page: 46-51
PDF size: 64.72 Kb.


ABSTRACT

The primary pulmonary arterial hypertension (PPH) is a disease with great functional limitation, poor prognosis in a few times, where the patients died for right ventricular failure. In the last decades, advances about knowledge in the pathobiology of the vascular endothelium, have contributed to new treatment with improvement of functional class for the patient and have had a reduction in the mortality. The most important advance in those treatments is the intravenous administration of prostacyclin. Initial treatment of this disease was the vasodilator without optimal results, from 1970 to 1990 when used calcium-channel blockers, oral anticoagulants, heart-lung transplant and from 1990 to 2000 the venous prostacyclin was used, which modified the mobility and mortality of this disease.
In the last years have appeared the endothelial inhibitors as bosentan, phosphodiesterasa inhibitors as sildenafil, also another forms of prostacyclin in subcutaneous way, oral or inhaled and other treatment non pharmacologic as the atrioseptostomy, those treatments pretend modified the morbimortality.


REFERENCES

  1. Roberts DH, Lepore JJ. Oxygen Therapy Improves Cardiac Index and Pulmonary Vascular Resistance in Patients with Pulmonary Hypertension. Chest 2001; 120:1547-1555.

  2. Rafanan AL. Nocturnal Hypoxemia is Common in Primary Pulmonary Hypertension. Chest 2001;120:894-899.

  3. Rich S, Kaufmann E. The Short Term Effects of Digoxin in Patients with Right Ventricular Dysfunction from Pulmonary Hypertension. Chest 1998;114:787-792.

  4. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary Pulmonary Hypertension: Natural History and the Importance of Thrombosis. Circulation 1984;70:580–587.

  5. Rich S, Kaufmann E, Levy PS. The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension. N Engl J Med 1992;327:76–81.

  6. Gildea TR. Treatments and Strategies to Optimize the Comprehensive Management of Patients with Pulmonary Arterial Hypertension. Cleve Clin J Med 2003;70:18S-27S.

  7. Lobo Beristain JL. Pauta de tratamiento de la hipertension pulmonar. Arc Bronconeumol 2003;38(1supl):24S-28S.

  8. Runo R, Loyd JE. Primary Pulmonary Hypertension. Lancet 2003;361:1533-1544.

  9. Naeije R, Vachiéry JL. Medical Therapy of Pulmonary Hypertension. Clin Chest Med 2001;22: 517-525.

  10. Lewis JR. Primary Pulmonary Hypertension. N Eng J Med 1997;336:111-117.

  11. Natale M, Piña INE. Evaluation of Pulmonary Hypertension in Heart Transplant Candidates. Curr Opinion Cardiol 2003;8:136-140.

  12. Inhbar S, Scjrader BJ, Kaufmann E. Effects of Adenosine in Combination with Calcium Channel Blockers in Patients with Primary Pulmonary Hypertension. J Am Coll Cardiol 1993;21:413-418.

  13. British Cardiac Society Guidelines and Medical Practice Committee. Recommendations on the Management of Pulmonary Hypertension in Clinical Practice Heart. Volume 86 Supplement I, September 1, 200l.

  14. Galie N, Manes A, Branzi A. Emerging Medical Therapies for Pulmonary Arterial Hypertension. Prog Cardiovasc Dis 2002;45:213-224.




2020     |     www.medigraphic.com